{"id":2678,"date":"2015-01-05T22:25:00","date_gmt":"2015-01-05T22:25:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2678"},"modified":"2025-01-16T15:36:34","modified_gmt":"2025-01-16T15:36:34","slug":"forecasting-the-disease-burden-of-chronic-hepatitis-c-virus-in-poland","status":"publish","type":"post","link":"https:\/\/cdafound.org\/es\/forecasting-the-disease-burden-of-chronic-hepatitis-c-virus-in-poland\/","title":{"rendered":"Previsi\u00f3n de la carga de morbilidad del virus de la hepatitis C cr\u00f3nica en Polonia"},"content":{"rendered":"<h2 class=\"wp-block-heading\">Resumen<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Antecedentes y objetivos<\/h3>\n\n\n\n<p>La infecci\u00f3n cr\u00f3nica por el virus de la hepatitis C prevalece entre 200.000 personas en Polonia; sin embargo, pocos conocen su enfermedad (30.000 diagnosticados) y a\u00fan menos reciben tratamiento (2490 en 2014). Este an\u00e1lisis proyect\u00f3 la carga de morbilidad futura y desarroll\u00f3 dos escenarios de tratamiento para controlar o eliminar la enfermedad relacionada con el virus de la hepatitis C en Polonia.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">M\u00e9todos<\/h3>\n\n\n\n<p>Utilizando un enfoque de modelado, se cuantific\u00f3 la poblaci\u00f3n infectada y la progresi\u00f3n futura de la enfermedad. Las variables iniciales incluyeron la prevalencia vir\u00e9mica, la edad y el sexo, la tasa de diagn\u00f3stico, la tasa de tratamiento, la progresi\u00f3n de la enfermedad y las tasas de respuesta virol\u00f3gica sostenida. Los datos se obtuvieron de la literatura y a trav\u00e9s de entrevistas a expertos.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Resultados<\/h3>\n\n\n\n<p>Se prev\u00e9 que el n\u00famero de infecciones prevalentes por el virus de la hepatitis C disminuya (5%) para 2030. Sin embargo, se estima que el n\u00famero de personas con cirrosis compensada y descompensada y carcinoma hepatocelular aumentar\u00e1 en 40, 55 y 60%, respectivamente. Al aumentar las tasas de respuesta virol\u00f3gica sostenida a 95% a partir de 2015 y el n\u00famero de casos tratados (de 2490 a 5000), se prev\u00e9 que el n\u00famero de personas con cirrosis, cirrosis descompensada y carcinoma hepatocelular se mantenga constante hasta 2030. Una estrategia para eliminar Tambi\u00e9n se consider\u00f3 la infecci\u00f3n cr\u00f3nica por el virus de la hepatitis C. Para reducir las infecciones totales en 90% y la mortalidad en 80%, el tratamiento se increment\u00f3 a 15.000 pacientes al a\u00f1o. Este escenario requiri\u00f3 el diagn\u00f3stico de 15.000 nuevos casos (frente a los 3000 actuales).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Conclusi\u00f3n<\/h3>\n\n\n\n<p>Es posible una marcada reducci\u00f3n de la carga de morbilidad relacionada con el virus de la hepatitis C, con un mayor diagn\u00f3stico y tratamiento. Los resultados podr\u00edan informar el desarrollo de una gesti\u00f3n eficaz de las enfermedades en Polonia.<\/p>\n\n\n\n<p><strong>Pa\u00edses:<\/strong> Polonia<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25426979\/\" target=\"_blank\" rel=\"noreferrer noopener\">Lea el informe completo<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary Background and Aims Chronic hepatitis C virus infection is prevalent among 200,000 individuals in Poland; however, few are aware of their condition (30,000 diagnosed) and even fewer are treated (2490 in 2014). This analysis projected future disease burden and developed two treatment scenarios to control or eliminate hepatitis C virus-related disease in Poland. Methods [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3306,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[10],"publication-author":[2104,2107,2106,2103,1118,2105],"class_list":["post-2678","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-hcv","publication-author-flisiak-r","publication-author-gower-ee","publication-author-halota-w","publication-author-kostrzewska-k","publication-author-razavi-ha","publication-author-tomasiewicz-k"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/comments?post=2678"}],"version-history":[{"count":6,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2678\/revisions"}],"predecessor-version":[{"id":7611,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2678\/revisions\/7611"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media\/3306"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media?parent=2678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/categories?post=2678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/tags?post=2678"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/publication-author?post=2678"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}